Leptin may be used as a biomarker of CVD risk in preadolescent children; more specifically, leptin concentrations > 13.4 ng/dL are significantly associated with MetS, while for every 1 ng/dL increase in leptin concentration, the odds of developing MetS and its complications increase by 3% [45,46]. This evidence concerns the gene LEP and metabolic syndrome.